Sienna Biopharmaceuticals, Inc. filed a motion in the US Bankruptcy Court for the sale of substantially all its assets on October 22, 2019. The debtor seeks the Court’s approval for the sale of substantially all its assets to the stalking horse bidder or the highest bidder through an auction. To qualify as a qualified bidder, interested parties should submit their bids by December 2, 2019, along with good-faith deposit in the amount of 10% of the purchase price. The debtor has scheduled an auction on December 5, 2019. The stalking horse bidder would be entitled to a break-up fee and expense reimbursement in case of termination of the asset purchase agreement. The sale hearing is scheduled for December 10, 2019.